Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.

Borden, Elizabeth S; Buetow, Kenneth H; Wilson, Melissa A; Hastings, Karen Taraszka

Borden, Elizabeth S; Buetow, Kenneth H; Wilson, Melissa A; Hastings, Karen Taraszka.

Afiliación

Borden ES; Department of Basic Medical Sciences, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, United States.
Buetow KH; Department of Research and Internal Medicine (Dermatology), Phoenix Veterans Affairs Health Care System, Phoenix, AZ, United States.
Wilson MA; School of Life Sciences, Arizona State University, Tempe, AZ, United States.
Hastings KT; Center for Evolution and Medicine, Arizona State University, Tempe, AZ, United States.

Front Oncol ; 12: 836821, 2022.

Article en En | MEDLINE | ID: mdl-35311072

Palabras clave

MHC class I; MHC class II; neoantigen prediction; neoantigen prioritization; neoantigens (neoAgs)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google